The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research

Donald A. Berry

doi:10.1016/j.molonc.2015.02.011

The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research

Donald A. Berry

Biostatistics

Research output: Contribution to journal › Review article › peer-review

106 Scopus citations

Abstract

Clinical trials are the final links in the chains of knowledge and for determining the roles of therapeutic advances. Unfortunately, in an important sense they are the weakest links. This article describes two designs that are being explored today: platform trials and basket trials. Both are attempting to merge clinical research and clinical practice.

Original language	English (US)
Pages (from-to)	951-959
Number of pages	9
Journal	Molecular oncology
Volume	9
Issue number	5
DOIs	https://doi.org/10.1016/j.molonc.2015.02.011
State	Published - May 1 2015

Keywords

Basket trials
Bayesian adaptive clinical trials
Biomarker-driven clinical trials
Platform trials

ASJC Scopus subject areas

Molecular Medicine
Genetics
Oncology
Cancer Research

Access to Document

10.1016/j.molonc.2015.02.011

Cite this

@article{836e1fade3094e92b6570a4cfc25cfa6,

title = "The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research",

abstract = "Clinical trials are the final links in the chains of knowledge and for determining the roles of therapeutic advances. Unfortunately, in an important sense they are the weakest links. This article describes two designs that are being explored today: platform trials and basket trials. Both are attempting to merge clinical research and clinical practice.",

keywords = "Basket trials, Bayesian adaptive clinical trials, Biomarker-driven clinical trials, Platform trials",

author = "Berry, {Donald A.}",

note = "Publisher Copyright: {\textcopyright} 2015 Federation of European Biochemical Societies.",

year = "2015",

month = may,

day = "1",

doi = "10.1016/j.molonc.2015.02.011",

language = "English (US)",

volume = "9",

pages = "951--959",

journal = "Molecular oncology",

issn = "1574-7891",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - The Brave New World of clinical cancer research

T2 - Adaptive biomarker-driven trials integrating clinical practice with clinical research

AU - Berry, Donald A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Clinical trials are the final links in the chains of knowledge and for determining the roles of therapeutic advances. Unfortunately, in an important sense they are the weakest links. This article describes two designs that are being explored today: platform trials and basket trials. Both are attempting to merge clinical research and clinical practice.

AB - Clinical trials are the final links in the chains of knowledge and for determining the roles of therapeutic advances. Unfortunately, in an important sense they are the weakest links. This article describes two designs that are being explored today: platform trials and basket trials. Both are attempting to merge clinical research and clinical practice.

KW - Basket trials

KW - Bayesian adaptive clinical trials

KW - Biomarker-driven clinical trials

KW - Platform trials

UR - http://www.scopus.com/inward/record.url?scp=84928587092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928587092&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2015.02.011

DO - 10.1016/j.molonc.2015.02.011

M3 - Review article

C2 - 25888066

AN - SCOPUS:84928587092

SN - 1574-7891

VL - 9

SP - 951

EP - 959

JO - Molecular oncology

JF - Molecular oncology

IS - 5

ER -

The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this